Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

The Human Medial Temporal Lobe Is Necessary for Remembering Durations within a Sequence of Events but Not Durations of Individual Events.

Palombo DJ, Reid AG, Thavabalasingam S, Hunsberger R, Lee ACH, Verfaellie M.

J Cogn Neurosci. 2020 Mar;32(3):497-507. doi: 10.1162/jocn_a_01489. Epub 2019 Oct 29.

PMID:
31659928
2.

Molecular Monitoring of Chronic Myeloid Leukemia.

Dominy K, Mokretar K, Reid AG, Khorashad JS.

Methods Mol Biol. 2020;2065:153-173. doi: 10.1007/978-1-4939-9833-3_12.

PMID:
31578694
3.

The hippocampus is necessary for the consolidation of a task that does not require the hippocampus for initial learning.

Schapiro AC, Reid AG, Morgan A, Manoach DS, Verfaellie M, Stickgold R.

Hippocampus. 2019 Nov;29(11):1091-1100. doi: 10.1002/hipo.23101. Epub 2019 Jun 3.

PMID:
31157946
4.

Self-related processing and future thinking: Distinct contributions of ventromedial prefrontal cortex and the medial temporal lobes.

Verfaellie M, Wank AA, Reid AG, Race E, Keane MM.

Cortex. 2019 Jun;115:159-171. doi: 10.1016/j.cortex.2019.01.028. Epub 2019 Feb 8.

PMID:
30826623
5.

Hippocampal contributions to value-based learning: Converging evidence from fMRI and amnesia.

Palombo DJ, Hayes SM, Reid AG, Verfaellie M.

Cogn Affect Behav Neurosci. 2019 Jun;19(3):523-536. doi: 10.3758/s13415-018-00687-8.

PMID:
30767129
6.

Childhood Sex-Typed Behavior and Gender Change in Individuals with 46,XY and 46,XX Disorders of Sex Development: An Iranian Multicenter Study.

Khorashad BS, Roshan GM, Reid AG, Aghili Z, Moghadam MD, Khazai B, Hiradfar M, Afkhamizadeh M, Ghaemi N, Talaei A, Abbaszadegan MR, Aarabi A, Dastmalchi S, Van de Grift TC.

Arch Sex Behav. 2018 Nov;47(8):2287-2298. doi: 10.1007/s10508-018-1281-9. Epub 2018 Aug 20.

PMID:
30128981
7.

Mental Health and Disorders of Sex Development/Intersex Conditions in Iranian Culture: Congenital Adrenal Hyperplasia, 5-α Reductase Deficiency-Type 2, and Complete Androgen Insensitivity Syndrome.

Khorashad BS, Aghili Z, Kreukels BPC, Reid AG, Roshan GM, Hiradfar M, Talaei A, Cohen Kettenis PT.

Arch Sex Behav. 2018 May;47(4):931-942. doi: 10.1007/s10508-017-1139-6. Epub 2018 Jan 2.

PMID:
29294229
8.

Development of artificial bone marrow fibre scaffolds to study resistance to anti-leukaemia agents.

Karimpoor M, IIlangakoon E, Reid AG, Claudiani S, Edirisinghe M, Khorashad JS.

Br J Haematol. 2018 Sep;182(6):924-927. doi: 10.1111/bjh.14883. Epub 2017 Aug 2. No abstract available.

PMID:
28771682
9.

Sexual orientation and medical history among Iranian people with Complete Androgen Insensitivity Syndrome and Congenital Adrenal Hyperplasia.

Khorashad BS, Roshan GM, Reid AG, Aghili Z, Hiradfar M, Afkhamizadeh M, Talaei A, Aarabi A, Ghaemi N, Taghehchian N, Saberi H, Farahi N, Abbaszadegan MR.

J Psychosom Res. 2017 Jan;92:55-62. doi: 10.1016/j.jpsychores.2016.12.002. Epub 2016 Dec 6.

PMID:
27998513
10.

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.

Alikian M, Whale AS, Akiki S, Piechocki K, Torrado C, Myint T, Cowen S, Griffiths M, Reid AG, Apperley J, White H, Huggett JF, Foroni L.

Clin Chem. 2017 Feb;63(2):525-531. doi: 10.1373/clinchem.2016.262824. Epub 2016 Dec 15.

11.

Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.

Khorashad JS, Tantravahi SK, Yan D, Mason CC, Qiao Y, Eiring AM, Gligorich K, Hein T, Pomicter AD, Reid AG, Kelley TW, Marth GT, O'Hare T, Deininger MW.

Leukemia. 2016 Nov;30(11):2275-2279. doi: 10.1038/leu.2016.218. Epub 2016 Aug 2. No abstract available.

12.

Using [(11)C]Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism.

Lingford-Hughes A, Myers J, Watson B, Reid AG, Kalk N, Feeney A, Hammers A, Riaño-Barros DA, McGinnity CJ, Taylor LG, Rosso L, Brooks DJ, Turkheimer F, Nutt DJ.

Neuroimage. 2016 May 15;132:1-7. doi: 10.1016/j.neuroimage.2016.02.005. Epub 2016 Feb 11.

13.

Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients.

Alikian M, Ellery P, Forbes M, Gerrard G, Kasperaviciute D, Sosinsky A, Mueller M, Whale AS, Milojkovic D, Apperley J, Huggett JF, Foroni L, Reid AG.

J Mol Diagn. 2016 Mar;18(2):176-89. doi: 10.1016/j.jmoldx.2015.09.005. Epub 2016 Feb 5.

14.

Investigating expectation and reward in human opioid addiction with [(11) C]raclopride PET.

Watson BJ, Taylor LG, Reid AG, Wilson SJ, Stokes PR, Brooks DJ, Myers JF, Turkheimer FE, Nutt DJ, Lingford-Hughes AR.

Addict Biol. 2014 Nov;19(6):1032-40. doi: 10.1111/adb.12073. Epub 2013 Jul 5.

15.

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.

Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, Alikian M, Reid AG, Foroni L, Marin D, Druker BJ, O'Hare T, Deininger MW.

Blood. 2013 Jan 17;121(3):489-98. doi: 10.1182/blood-2012-05-431379. Epub 2012 Dec 5.

16.

Substance abuse disorders.

Reid AG, Lingford-Hughes AR, Cancela LM, Kalivas PW.

Handb Clin Neurol. 2012;106:419-31. doi: 10.1016/B978-0-444-52002-9.00024-3. Review. No abstract available.

PMID:
22608635
17.

BCL3 rearrangement, amplification and expression in diffuse large B-cell lymphoma.

Ibrahim HA, Amen F, Reid AG, Naresh KN.

Eur J Haematol. 2011 Dec;87(6):480-5. doi: 10.1111/j.1600-0609.2011.01684.x. Epub 2011 Aug 19.

PMID:
21752100
18.

T cell lymphoblastic leukaemia/lymphoma associated with a microenvironment of thymic asteroid B cells in the bone marrow.

Naresh KN, May PC, Reid AG, Marks AJ, Macdonald D, Kanfer E.

Histopathology. 2010 Oct;57(4):549-54. doi: 10.1111/j.1365-2559.2010.03663.x. Epub 2010 Sep 28.

PMID:
20875071
19.

A [11C]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced α5 benzodiazepine receptors in limbic regions.

Lingford-Hughes A, Reid AG, Myers J, Feeney A, Hammers A, Taylor LG, Rosso L, Turkheimer F, Brooks DJ, Grasby P, Nutt DJ.

J Psychopharmacol. 2012 Feb;26(2):273-81. doi: 10.1177/0269881110379509. Epub 2010 Sep 24.

PMID:
20870689
20.

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.

Daghistani M, Marin D, Khorashad JS, Wang L, May PC, Paliompeis C, Milojkovic D, De Melo VA, Gerrard G, Goldman JM, Apperley JF, Clark RE, Foroni L, Reid AG.

Blood. 2010 Dec 23;116(26):6014-7. doi: 10.1182/blood-2010-01-264234. Epub 2010 Sep 20.

PMID:
20855863
21.

Variant isoforms of BCR-ABL1 in chronic myelogenous leukemia reflect alternative splicing of ABL1 in normal tissue - letter.

Khorashad JS, Milojkovic D, Reid AG.

Mol Cancer Ther. 2010 Jul;9(7):2152. doi: 10.1158/1535-7163.MCT-10-0311. Epub 2010 Jun 22. No abstract available.

22.

hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.

Bazeos A, Marin D, Reid AG, Gerrard G, Milojkovic D, May PC, de Lavallade H, Garland P, Rezvani K, Apperley JF, Goldman JM, Foroni L, Khorashad JS.

Leukemia. 2010 Jun;24(6):1243-5. doi: 10.1038/leu.2010.86. Epub 2010 May 6. No abstract available.

PMID:
20445576
23.

Specific patterns of chromosomal gains and losses associate with t(3;14), t(8;14), and t(14;18) in diffuse large B-cell lymphoma.

Sheth A, de Melo VA, Szydlo R, Macdonald DH, Reid AG, Wagner SD.

Cancer Genet Cytogenet. 2009 Oct;194(1):48-52. doi: 10.1016/j.cancergencyto.2009.05.011.

PMID:
19737654
24.

Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?

Marin D, Khorashad JS, Foroni L, Milojkovic D, Szydlo R, Reid AG, Rezvani K, Bua M, Goldman JM, Apperley JF.

Br J Haematol. 2009 May;145(3):373-5. doi: 10.1111/j.1365-2141.2009.07646.x. Epub 2009 Mar 12.

PMID:
19344397
25.

Phenotype of blasts in chronic myeloid leukemia in blastic phase-Analysis of bone marrow trephine biopsies and correlation with cytogenetics.

Reid AG, De Melo VA, Elderfield K, Clark I, Marin D, Apperley J, Naresh KN.

Leuk Res. 2009 Mar;33(3):418-25. doi: 10.1016/j.leukres.2008.07.019. Epub 2008 Aug 28.

PMID:
18760473
26.

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, Foroni L, Rezvani K, Bua M, Dazzi F, Pavlu J, Klammer M, Kaeda JS, Goldman JM, Apperley JF.

Blood. 2008 Dec 1;112(12):4437-44. doi: 10.1182/blood-2008-06-162388. Epub 2008 Aug 20.

27.

Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis.

Khorashad JS, De Melo VA, Fiegler H, Gerrard G, Marin D, Apperley JF, Goldman JM, Foroni L, Reid AG.

Leukemia. 2008 Sep;22(9):1806-7. doi: 10.1038/leu.2008.210. Epub 2008 Jul 31. No abstract available.

PMID:
18668129
28.

Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.

Khorashad JS, de Lavallade H, Apperley JF, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, Marin D.

J Clin Oncol. 2008 Oct 10;26(29):4806-13. doi: 10.1200/JCO.2008.16.9953. Epub 2008 Jul 21.

PMID:
18645191
29.

FISH mapping of Philadelphia negative BCR/ABL1 positive CML.

Virgili A, Brazma D, Reid AG, Howard-Reeves J, Valgañón M, Chanalaris A, De Melo VA, Marin D, Apperley JF, Grace C, Nacheva EP.

Mol Cytogenet. 2008 Jul 18;1:14. doi: 10.1186/1755-8166-1-14.

30.

A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia.

Khorashad JS, Thelwell N, Milojkovic D, Marin D, Watson JA, Goldman JM, Apperley JF, Foroni L, Reid AG.

J Clin Pathol. 2008 Jul;61(7):863-5. doi: 10.1136/jcp.2008.056804.

PMID:
18587017
31.

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.

de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, Marin D.

J Clin Oncol. 2008 Jul 10;26(20):3358-63. doi: 10.1200/JCO.2007.15.8154. Epub 2008 Jun 2.

PMID:
18519952
32.

Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements.

De Melo VA, Milojkovic D, Marin D, Apperley JF, Nacheva EP, Reid AG.

Cancer Genet Cytogenet. 2008 Apr 15;182(2):111-5. doi: 10.1016/j.cancergencyto.2008.01.007.

PMID:
18406872
33.

Reduced thalamic grey matter volume in opioid dependence is influenced by degree of alcohol use: a voxel-based morphometry study.

Reid AG, Daglish MR, Kempton MJ, Williams TM, Watson B, Nutt DJ, Lingford-Hughes AR.

J Psychopharmacol. 2008 Jan;22(1):7-10. doi: 10.1177/0269881107080795.

PMID:
18187528
34.

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.

Khorashad JS, Milojkovic D, Mehta P, Anand M, Ghorashian S, Reid AG, De Melo V, Babb A, de Lavallade H, Olavarria E, Marin D, Goldman JM, Apperley JF, Kaeda JS.

Blood. 2008 Feb 15;111(4):2378-81. Epub 2007 Nov 2.

PMID:
17982022
35.

Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia.

De Melo VA, Milojkovic D, Khorashad JS, Marin D, Goldman JM, Apperley JF, Reid AG.

Blood. 2007 Oct 15;110(8):3086-7. No abstract available.

PMID:
17916757
36.

A simple FISH assay for the detection of 3q26 rearrangements in myeloid malignancy.

De Melo V, Vetter M, Mazzullo H, Howard JD, Betts DR, Nacheva EP, Apperley JF, Reid AG.

Leukemia. 2008 Feb;22(2):434-7. Epub 2007 Sep 13. No abstract available.

PMID:
17851560
37.

A t(12;17)(p13;q12) identifies a distinct TEL rearrangement-negative subtype of precursor-B acute lymphoblastic leukemia.

Reid AG, Seppa L, von der Weid N, Niggli FK, Betts DR.

Cancer Genet Cytogenet. 2006 Feb;165(1):64-9.

PMID:
16490598
39.

Genesis of derivative chromosome 9 deletions in chronic myeloid leukemia.

Reid AG, Nacheva EP.

Genes Chromosomes Cancer. 2005 Jun;43(2):223-4; author reply 225. No abstract available.

PMID:
15751036
40.

Double Philadelphia masquerading as chromosome 20q deletion--a new recurrent abnormality in chronic myeloid leukaemia blast crisis.

Reid AG, Swanton S, Grace C, Campbell LJ, Green AR, Nacheva EP; United Kingdom Cancer Cytogenetics Group (UKCCG).

Br J Haematol. 2003 Nov;123(3):442-8.

PMID:
14617003
41.

A potential role for PRDM12 in the pathogenesis of chronic myeloid leukaemia with derivative chromosome 9 deletion.

Reid AG, Nacheva EP.

Leukemia. 2004 Jan;18(1):178-80. No abstract available.

PMID:
14523459
42.

Molecular cytogenetics of polycythaemia vera: lack of occult rearrangements detectable by 20q LSP screening, CGH, and M-FISH.

Gribble SM, Reid AG, Bench AJ, Huntly BJ, Grace C, Green AR, Nacheva EP.

Leukemia. 2003 Jul;17(7):1419-21. No abstract available.

PMID:
12835736
43.

Genomic imbalances in CML blast crisis: 8q24.12-q24.13 segment identified as a common region of over-representation.

Gribble SM, Reid AG, Roberts I, Grace C, Green AR, Nacheva EP.

Genes Chromosomes Cancer. 2003 Aug;37(4):346-58.

PMID:
12800146
44.
45.

Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.

Huntly BJ, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C, Byrne J, Brizard A, Niederwieser D, Freeman-Edward J, Cuthbert G, Bown N, Clark RE, Nacheva EP, Green AR, Deininger MW.

Blood. 2003 Sep 15;102(6):2205-12. Epub 2003 May 15.

PMID:
12750153
46.

Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia.

Reid AG, Huntly BJ, Grace C, Green AR, Nacheva EP.

Br J Haematol. 2003 May;121(3):419-27.

PMID:
12716364
47.

Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability.

Huntly BJ, Bench AJ, Delabesse E, Reid AG, Li J, Scott MA, Campbell L, Byrne J, Pinto E, Brizard A, Niedermeiser D, Nacheva EP, Guilhot F, Deininger M, Green AR.

Blood. 2002 Jun 15;99(12):4547-53.

PMID:
12036887
48.

Deletions of the derivative chromosome 9 do not account for the poor prognosis associated with Philadelphia-positive acute lymphoblastic leukemia.

Reid AG, Huntly BJ, Hennig E, Niederwieser D, Campbell LJ, Bown N, Telford N, Walker H, Grace CD, Deininger MW, Green AR, Nacheva EP.

Blood. 2002 Mar 15;99(6):2274-5. No abstract available.

PMID:
11902139
49.

Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia.

Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, Szer J, Prince HM, Turner P, Grace C, Nacheva EP, Green AR.

Blood. 2001 Sep 15;98(6):1732-8.

PMID:
11535505
50.

Colon resection nomenclature: a practical problem in surgical audit.

Gordon DS, Reid AG.

J R Coll Surg Edinb. 1986 Jun;31(3):164-8. No abstract available.

PMID:
3772857

Supplemental Content

Support Center